Trial Profile
A Phase 2, Open-label, Single-arm, Efficacy and Safety Study of Enzalutamide (MDV3100) in Patients With Hormone-naive Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 31 Aug 2017 Results (data cut off April 16, 2015) of prespecified 3 year followup analysis published in the Journal of Urology
- 18 Feb 2017 Results of a pre-specified 3-year follow-up, presented at the 2017 Genitourinary Cancers Symposium.
- 05 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Mar 2017 as reported by ClinicalTrials.gov.